EudraVigilance数据库:母乳喂养婴儿的可疑药物不良反应分析
该研究分析了EudraVigilance数据库2013年1月至2023年7月报告的母乳喂养婴儿可疑药物不良反应(ADR),共纳入922例,其中严重ADR 133例(14%),死亡15例,主要与美沙酮(n=11)和二乙酰吗啡(n=3)相关;COVID-19疫苗相关报告占52%(n=479),严重ADR主要涉及神经系统药物(n=73,43%)。研究者认为相对于欧洲每年数百万经母乳暴露药物的婴儿,报告率极低,提示上市后监测存在严重报告不足。
要点
- 母乳喂养婴儿中严重ADR占14%,死亡15例主要与美沙酮和二乙酰吗啡相关。
- COVID-19疫苗相关报告占52%,但严重ADR主要涉及神经系统药物(抗惊厥药和阿片类)。
- 多数病例(55%)发生于1月龄至1岁婴儿,提示该年龄段需重点关注。
核心结论
- 母乳喂养婴儿中可疑ADR报告率极低,提示药物警戒存在严重报告不足。
- 严重ADR主要与美沙酮、二乙酰吗啡等神经系统药物相关。
研究设计与样本
- 基于EudraVigilance数据库的回顾性分析,纳入2013年1月1日至2023年7月1日所有怀疑与母乳传播药物相关的婴儿ADR报告。
- 共纳入922例可疑ADR报告,按报告时间、婴儿年龄和性别、严重性、ADR类型及涉及药物分类。
主要发现
- 共报告922例可疑ADR,严重ADR 133例(14%),死亡15例。
- 死亡病例主要与美沙酮(n=11)和二乙酰吗啡(n=3)相关。
- COVID-19疫苗相关报告占52%(n=479)。
- 严重ADR主要涉及神经系统药物(n=73,43%),尤其是抗惊厥药和阿片类。
- 多数病例(n=511,55%)发生于1月龄至1岁婴儿。
临床怎么用
- 临床应关注母乳喂养婴儿中与母亲使用美沙酮、二乙酰吗啡等神经系统药物相关的严重ADR风险。
- 对1月龄至1岁婴儿的母亲用药需加强监测,警惕ADR表现。
- 临床医生应主动识别和上报母乳喂养相关ADR,以改善药物警戒报告不足。
局限性
- 基于自发报告数据库,存在报告不足和报告偏倚。
- 无法计算真实发生率,仅能描述报告特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We aimed to describe suspected adverse drug reactions (ADRs) in infants resulting from medications transmitted through mothers' milk, as reported to the European ADR database, EudraVigilance. The research sought to understand the frequency, seriousness and nature of these ADRs to assess potential risks associated with maternal medication use during breastfeeding. METHODS: Data from EudraVigilance were analysed. The study included all reported ADRs suspected to be related to medications transmitted through mothers' milk from 1 January 2013 to 1 July 2023. The data were categorized by reporting time, infant age and sex, seriousness and type of ADR, and the medications involved. RESULTS: A total of 922 suspected ADRs were reported in breastfed infants. Serious ADRs accounted for 133 cases (14%), with 15 reported fatalities, primarily associated with methadone (n = 11) and diamorphine (n = 3). COVID-19 vaccines were linked to half of the suspected ADR reports (n = 479, 52%), while serious ADRs were mainly associated with nervous system drugs (n = 73, 43%), particularly anticonvulsants and opioids. Most cases (n = 511, 55%) occurred in infants aged between 1 month and 1 year. CONCLUSIONS: The reporting of 922 ADRs in breastfed infants over a decade, compared to the estimated millions of infants exposed to medications via mothers' milk annually in Europe, suggests a very low reporting rate of suspected ADRs. This finding emphasizes the significant challenges in postmarketing surveillance and suggests that underreporting remains a critical concern in pharmacovigilance.
引用
- Heerfordt IM, Gotfredsen DR, Horwitz H, et al. EudraVigilance insights: Suspected adverse drug reactions in infants through breastfeeding. Br J Clin Pharmacol. 2025. PMID: 40190021. doi:10.1002/bcp.70063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。